Navigation Links
Luminex Corporation Announces Agreement to Acquire GenturaDx
Date:7/9/2012

ual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex' actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex' products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex' ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex' foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to successfully integrate acquired companies, including GenturaDx, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex' Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements, including the financial guidance and 2012 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements
'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Luminex Corporation Reports First Quarter 2012 Results
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
4. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
5. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
6. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
7. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
8. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
11. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... DUBLIN , May 27, 2015 /PRNewswire/ ... ) has announced the addition of the  ... Testing Market"  report to their offering.  ... ,This comprehensive five-country report contains 500 pages, ... current suppliers and potential market entrants identify ...
(Date:5/27/2015)... May 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity ... patients suffer from a series of diverse complications arising ... the blood or tissues, which cause a rapidly progressing ... mortality rates near 50% depending on disease severity. The ... systems of the global marketplace, which for the purposes ...
(Date:5/27/2015)... PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market ... is an autoimmune disease that permanently destroys beta cells of ... longer produce insulin. Over the last 90 years, insulin therapy ... can be offered to a patient who is newly diagnosed ... of action - long-acting as well as short or rapid-acting ...
Breaking Medicine Technology:European Hemostasis Diagnostic Testing Market Strategies 2015 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4
... CITY, Calif., July 7 Relievant Medsystems, Inc., developer ... back pain, reported today that it has completed a ... led by Morgenthaler Ventures with existing investors Canaan Partners ... participating. The company also announced that Morgenthaler partner ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: SNY ... study of Lantus(R) (insulin glargine [rDNA] injection) versus NPH insulin ... published on-line in Diabetologia ... in the two treatment groups. This is the longest controlled ...
Cached Medicine Technology:Relievant Medsystems Announces Completion of $20 Million Financing 2Relievant Medsystems Announces Completion of $20 Million Financing 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 25-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 35-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 45-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH 5
(Date:5/28/2015)... The Cancer Solution: Taking Charge of Your ... and heartfelt book the Booksandauthor reviewer ever read ... for writing what should be one of the most important ... is power in action and this book has both. , ... talk about and unfortunately many persons know little about it. ...
(Date:5/28/2015)... 2015 The 110-mile April 24-26 ... from national non-profit World T.E.A.M. Sports is featured in ... With Heroes . , Host Bob Calvert and videographers ... and civilian riders, sponsors and staff members. The April ... a musical performance by The American Bombshells and a ...
(Date:5/27/2015)... (PRWEB) May 28, 2015 Calls Upon Individuals, ... , A new nationwide initiative – a “Summer of Service” ... create and build partnerships to grow the number of individuals ... renewing its commitment to Veterans by inviting the community to ... house June 29, 2015 from 1 – 3:00 p.m. in ...
(Date:5/27/2015)... is a reputable source of 2015 NHL Western Conference Finals ... of their series against the Anaheim Ducks with the Ducks currently ... win tonight at home, this will tie up the series with ... Center in Anaheim. , During the regular season, the Ducks ... won the Pacific Division by 8 points ahead of the second ...
(Date:5/27/2015)... Beverly Hills, CA (PRWEB) May 27, 2015 ... state of the art web portal focussed on keratoconus ... disease. This relentless progressive disease has its onset in the ... quieting down. The cornea or the front clear part of ... withstand the pressure in the eye. It results in poor ...
Breaking Medicine News(10 mins):Health News:Booksandauthor Cites The Cancer Solution as One of the Most Important Books to Read 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 2Health News:Videos Document World T.E.A.M. Sports' April 24-26 Face of America Bicycling Ride to Gettysburg 3Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2
... for Prescription Prenatal Vitamins , , ... once-daily prescription prenatal vitamin in its category, delivering the most ... ST. LOUIS, Dec. 17 KV Pharmaceutical Company (NYSE: ... - the U.S. market leader in branded prenatal vitamins ...
... Mass., Dec. 17 Biopure Corporation (Nasdaq: ... the Food and Drug Administration (FDA) an investigational new ... 2 clinical trial of the company,s oxygen therapeutic Hemopure(R) ... trial Hemopure would be studied for use ...
... Closed the Amendment of the , -------------------------------------------------------------------- ... Notes , ------------------------------------------------- , ... BELLUS Health Inc. (NASDAQ: BLUS ; TSX: ... the NASDAQ Stock Market of its intention to voluntarily ...
... leaders pay tribute to Africa Mercy crew and commit to continue progress. ... and general Mercy Ships footage are available for download with registration at ... ... 2008 -- The Africa Mercy pulled out of the Free ...
... and B2B Marketing Pro Toby Younis today announced a free webcast ... The webcast is designed for executives in B2B companies facing challenging ... ... DC (PRWEB) December 17, 2008-- Widely recognized B2B marketing expert ...
... Physician Hospitals of America (PHA) is applauding President-elect Barack Obama,s ... Department of Health and Human Services in his Cabinet. , ... U.S. Senator from South Dakota, is both known and respected ... Falls. , , "Tom Daschle ...
Cached Medicine News:Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 2Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 3Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 4Health News:KV Pharmaceutical Launches Enhanced Formulation of PrimaCare ONE(R) 5Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 2Health News:Biopure Submits IND Application for Proposed Clinical Trial in Patients with Acute Myeloid Leukemia 3Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 2Health News:BELLUS Health announces formal notice to voluntarily delist from NASDAQ 3Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 2Health News:Mercy Ship Sails On From Liberia After Four-Year Rebuilding Effort 3Health News:B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking" 2Health News:Physician Hospitals of America (PHA) Applauds President-Elect Obama's Selection of Sen. Daschle as HHS Secretary 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... DIFF CHEK-30 is a rapid ELISA ... 100% negative predictive value and 99% sensitivity. ... and cost-effectively screen out C. difficile negatives ... of samples - before culturing for the ...
Medicine Products: